All Posts

Friday, January 16, 2026 – Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments

Wednesday, January 14, 2026 – JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear

Tuesday, November 11, 2025 – Some people will get itching at the site of injection of the GLP-1 drugs. This is not common but is irritating. There are some things you can do to lessen the severity of the reaction.

Thursday, November 6, 2025 – President Trump’s plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.

Friday, October 31, 2025 – A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new

Saturday, October 18, 2025 – Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.

Sunday, August 3, 2025 – The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity

Sunday, August 3, 2025 – A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans

Friday, August 1, 2025 – The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal

Thursday, July 31, 2025 – This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and

Saturday, July 26, 2025 – This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle

Wednesday, July 23, 2025 – The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which

Tuesday, July 22, 2025 – “FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications.

Sunday, July 20, 2025 – A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass

Friday, July 18, 2025 – This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights

Thursday, July 17, 2025 – This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health

Wednesday, July 16, 2025 – A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing,

Tuesday, July 15, 2025 – The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared

Sunday, July 13, 2025 – The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces

Saturday, July 12, 2025 – This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP)

Friday, July 11, 2025 – This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients

Thursday, July 10, 2025 – There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a

Monday, July 7, 2025 – The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug

Saturday, July 5, 2025 – This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from

Monday, June 30, 2025 – We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to

Monday, June 30, 2025 – Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to

Tuesday, June 24, 2025 – This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults

Tuesday, June 24, 2025 – https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these

Sunday, June 22, 2025 – This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy

Thursday, June 19, 2025 – 🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist,

Sunday, June 15, 2025 – Kommu S, Sharma PP, Gabor RM. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of

Monday, June 9, 2025 – Wikipedia is a free, multilingual, web-based, and openly editable encyclopedia maintained by a global community of volunteers. It’s hosted by the non-profit Wikimedia Foundation. Wikipedia offers articles on

Monday, June 9, 2025 – Definition and diagnostic criteria of clinical obesityRubino, Francesco et al.The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 262 The Lancet Diabetes & Endocrinology